{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:55Z","timestamp":1786119655409,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only 41.9% of girls in the recommended age group, and only 28.1% of males in the recommended age group have received all recom-mended doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low. The U.S. Food and Drug Administration has approved three vaccines that are effective at preventing HPV infection. These vaccines cover 2, 4, or 9 HPV serotypes, respectively. Safety data for all three HPV vaccines are reassuring. The HPV vaccines are recommended for girls and boys aged 11\u201312 years and can be given to females and males up to age 26 years. The Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11\u201312 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection. Obstetrician\u2013gynecologists and other health care providers should stress to parents and patients the benefits and safety of HPV vaccination and offer HPV vaccines in their offices.<\/jats:p>","DOI":"10.1097\/aog.0000000000002052","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T10:15:00Z","timestamp":1490436900000},"page":"e173-e178","source":"Crossref","is-referenced-by-count":50,"title":["Committee Opinion No. 704: Human Papillomavirus Vaccination"],"prefix":"10.1097","volume":"129","member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.virol.2013.04.023","article-title":"Cross-roads in the classification of papillomaviruses","volume":"445","author":"de Villiers","year":"2013","journal-title":"Virology"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"661","DOI":"10.15585\/mmwr.mm6526a1","article-title":"Human papillomavirus-associated cancers\u2014United States, 2008\u20132012","volume":"65","author":"Viens","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"R5-20230711","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"U.S. assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1055-9965.EPI-14-0649","article-title":"HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. HPV-IMPACT Working Group","volume":"24","author":"Hariri","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.otpol.2014.05.004","article-title":"HPV vaccination in head and neck HPV-related pathologies","volume":"68","author":"Wierzbicka","year":"2014","journal-title":"Otolaryngol Pol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"issue":"65","key":"R11-20230711","first-page":"850","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States","volume":"2016","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2014updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"J Clin Virol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2012-1516","article-title":"Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds","volume":"130","author":"Bednarczyk","year":"2012","journal-title":"Pediatrics"},{"issue":"suppl 5","key":"R15-20230711","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"65","key":"R16-20230711","first-page":"1","article-title":"Youth risk behavior surveillance\u2014United States","volume":"2016","author":"Kann","year":"2015","journal-title":"MMWR Surveill Summ"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. HPV PATRICIA Study Group [published erratum appears in Lancet 2010;376:1054]","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R20-20230711","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Centers for Disease Control and Prevention (CDC)","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-05","key":"R21-20230711","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"Centers for Disease Control and Prevention (CDC) [published erratum appears in MMWR Morb Mortal Wkly Rep"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"R23-20230711","first-page":"138","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials. Quadrivalent Human Papillomavirus Vaccine Phase III Investigators","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. IMPAACT P1047 Protocol Team","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/152460900318957","article-title":"Acceptability of human papillomavirus immunization","volume":"9","author":"Zimet","year":"2000","journal-title":"J Womens Health Gend Based Med"},{"key":"R29-20230711","first-page":"591","article-title":"2007\u20132012, and postlicensure vaccine safety monitoring, 2006\u20132013\u2014United States. Centers for Disease Control and Prevention (CDC)","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201706000-00052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:49Z","timestamp":1786041949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201706000-00052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002052","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}